You are here: Industry Insights > Market News > DRL receives US FDA’s approval for XEGLYZETM (abametapir) lotion

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

Hot Products

Propantheline Bromide

carbomer 974P

Coenzyme Q10

Refined Fish Oil

Black Currant Extract

Hydrocortisone

DRL receives US FDA’s approval for XEGLYZETM (abametapir) lotion

expresspharmaJuly 28, 2020

Tag: Dr Reddy , XEGLYZE , FDA

Favorites

Dr Reddy’s Laboratories announced approval of XEGLYZE (abametapir) lotion, 0.74 per cent, a 505(b)(1) NDA by the US Food and Drug Administration (US FDA).

The approval triggers the contractual pre-commercialization milestone of $20 million payable to Hatchtech. XEGLYZE is indicated for the topical treatment of head lice infestation in patients 6 months of age and older. The company is working to commercialize this product through partners.

Previous:Interview Changzhou Golden Bright Pharmaceutical Factory: How to achieve safe production while ensuring quality?

Next:Five sites in India ready for Oxford-AstraZeneca COVID-19 vaccine trial: DBT

InnoCare Sets up Specific Environment Management Target in its Fifth ESG Report

PharmaSourcesApril 28, 2024

InnoCare Pharma, a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases.

Touchlight Awarded Grant Extension to Further Develop DNA-Enabled Biobatteries with U.S. Office for Naval Research and UK Defence Science & Technology Laboratory

Biotech NewswireApril 26, 2024

Study Results of Orelabrutinib in Patients with ITP Published by the American Journal of Hematology

PharmaSourcesApril 18, 2024

DRL receives US FDA’s approval for XEGLYZETM (abametapir) lotion | Pharmasources.com

Autonomix Medical Inc. Covered in Benzinga Article Highlighting Innovative Nerve Treatment Technology

PharmaSourcesApril 17, 2024

Company is targeting pancreatic cancer pain with advanced nerve detection and treatment technology

DRL receives US FDA’s approval for XEGLYZETM (abametapir) lotion

Related News

InnoCare Sets up Specific Environment Management Target in its Fifth ESG Report

Touchlight Awarded Grant Extension to Further Develop DNA-Enabled Biobatteries with U.S. Office for Naval Research and UK Defence Science & Technology Laboratory

Study Results of Orelabrutinib in Patients with ITP Published by the American Journal of Hematology

Autonomix Medical Inc. Covered in Benzinga Article Highlighting Innovative Nerve Treatment Technology

You may like